|
- Dalbavancin - Wikipedia
Dalbavancin is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA)
- Dalbavancin Uses, Side Effects Warnings - Drugs. com
What is dalbavancin? Dalbavancin is an antibiotic that fights bacteria Dalbavancin is used to treat severe skin infections caused by bacteria Dalbavancin may also be used for purposes not listed in this medication guide
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin . . .
Dalbavancin (Durata Therapeutics) is a lipoglycopeptide antibiotic agent with in vitro and in vivo activity against gram-positive pathogens, including a minimal inhibitory concentration (MIC)
- DALVANCE label - Food and Drug Administration
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat infections that are proven
- Dalvance (dalbavancin) dosing, indications, interactions, adverse . . .
Medscape - Infection dosing for Dalvance (dalbavancin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation schedules, and cost information
- Dalbavancin (intravenous route) - Side effects uses
Dalbavancin injection is used to treat acute bacterial skin and skin structure infections (ABSSSI) It belongs to the group of medicines known as antibiotics Dalbavancin works by killing bacteria or preventing their growth Dalbavancin will not work for colds, flu, or other virus infections
- Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity . . .
This review will serve to introduce dalbavancin, review pertinent in vitro and clinical data, and discuss possible future therapeutic uses for dalbavancin outside the currently FDA-approved indication
- DALBAVANCIN FOR INJECTION DOSAGE FORMS AND STRENGTHS INDICATIONS AND . . .
Dalbavancin for injection is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin- susceptible and methicillin-resistant isolates
|
|
|